natgillin/translations-raw huggingface dataset:
After five days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic gastroesophageal reflux disease (GERD) patients.
Po petih dneh peroralne uporabe 20 mg esomeprazola pri simptomatskih bolnikih z gastroezofagealno refluksno boleznijo (GERB) je bil želodčni pH nad 4 povprečno 13 ur, po petih dneh peroralne uporabe 40 mg esomeprazola pa povprečno 17 ur v 24 urah.
The capsules should be swallowed whole with half a glass of water.
Način uporabe Kapsule je treba zaužiti cele s pol kozarca vode.
• Inflammation of the gut (leading to diarrhoea).
• vnetje v črevesu (ki povzroči drisko)
• An inflammation on the inside of the mouth.
• vnetje v ustih
If your symptoms worsen or do not improve after taking this medicine for 14 days in a row, contact your doctor.
Če se znaki vaše bolezni poslabšajo ali ne izboljšajo po jemanju tega zdravila 14 dni zapored, se posvetujte z zdravnikom.
Concomitant administration of esomeprazole has been reported to increase the serum levels of tacrolimus.
Opisano je, da sočasna uporaba esomeprazola zviša koncentracijo takrolimusa v serumu.
Protease inhibitors
Zaviralci proteaz
Very rare (may affect up to 1 in 10,000 people)
Zelo redki (pojavijo se lahko pri največ 1 od 10.000 oseb)
• Methotrexate (used to treat cancer and rheumatic disorders)
• metotreksat (uporablja se za zdravljenje raka in revmatskih bolezni)
- The other ingredients are glycerol monostearate 40-55, hydroxypropylcellulose, hypromellose, reddish-brown iron oxide (E172), yellow iron oxide (E172), magnesium stearate, methacrylic acid ethylacrylate copolymer (1:1) dispersion 30 per cent, cellulose microcrystalline, synthetic paraffin, macrogol 6000, polysorbate 80, crospovidone (Type A), sodium stearyl fumarate, sugar spheres (sucrose and maize starch), talc, titanium dioxide (E171) and triethyl citrate (see section 2, “Nexium Control contains sucrose”).
- Druge sestavine zdravila so glicerilmonostearat 40-55, hidroksipropilceluloza, hipromeloza, rdeče rjavi železov oksid (E172), rumeni železov oksid (E172), magnezijev stearat, metakrilna kislina in etilakrilat, kopolimer (1:1), 30-odstotna disperzija, mikrokristalna celuloza, sintetični parafin, makrogol 6000, polisorbat 80, krospovidon (vrsta A), natrijev stearilfumarat, sladkorne kroglice (saharoza in koruzni škrob), smukec, titanov dioksid (E171) in trietilcitrat (glejte poglavje 2 "Zdravilo Nexium Control vsebuje saharozo").
Swallow whole.
Pogoltnite celo.
The pellets should not be chewed or crushed.
Zrnc se ne sme žvečiti ali zdrobiti.
Gastro-resistant hard capsule.
Trda gastrorezistentna kapsula (gastrorezistentna kapsula).
This may cause weakness, being sick (vomiting) and cramps
To lahko povzroči šibkost, slabost (bruhanje) in krče.
Esomeprazole inhibits CYP2C19, the major esomeprazole metabolising enzyme.
Esomeprazol zavira CYP2C19, ki je glavni encim za presnovo esomeprazola.
• St. John's wort (Hypericum perforatum) (used to treat depression)
• šentjanževko (Hypericum perforatum) (uporablja se za zdravljenje depresije)
Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5).
Sočasna uporaba esomeprazola in atazanavirja ni priporočljiva (glejte poglavje 4.5).
The proportion of patients maintaining an intragastric pH above 4 for at least 8, 12 and 16 hours respectively were for esomeprazole 20 mg 76%, 54%, and 24%.
Po 20 mg esomeprazola je bil želodčni pH nad 4 vsaj 8 ur pri 76 % bolnikov, vsaj 12 ur pri 54 % bolnikov in vsaj 16 ur pri 24 % bolnikov.
• Severe kidney problems.
• hude težave z ledvicami
One tablet daily Lasts 24 hours
Zdravi zgago in refluks želodčne kisline ena tableta na dan deluje 24 ur
Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg twice a day (b.i.d.
Sočasna uporaba esomeprazola in zaviralca CYP3A4, klaritromicina (500 mg dvakrat na dan) je podvojila izpostavljenosti (AUC) esomeprazolu.
The tablets should be swallowed whole with half a glass of water.
Način uporabe Tablete je treba zaužiti cele s pol kozarca vode.
EU/1/13/860/003 14 gastro-resistant capsules
EU/1/13/860/003 14 gastrorezistentnih kapsul
Skin and subcutaneous tissue disorders dermatitis, pruritus, rash urticaria alopecia, photosensitivity erythema multiforme, StevensJohnson syndrome, toxic epidermal necrolysis (TEN)
Bolezni kože in podkožja dermatitis, srbenje, izpuščaj, urtikarija alopecija, fotosenzibilnost multiformni eritem,
What Nexium Control contains
Kaj vsebuje zdravilo Nexium Control
• You are over 55 and have new or recently changed reflux symptoms.
• ste starejši od 55 let in se vam pojavijo novi simptomi refluksa ali se vam takšni simptomi v zadnjem času spremenijo.
For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported during concomitant omeprazole treatment (40 mg once a day).
Med hkratnim zdravljenjem s sakvinavirjem (sočasno z ritonavirjem) in omeprazolom (40 mg enkrat na dan) je bila koncentracija sakvinavirja v serumu večja (80-100 %).
14 gastro-resistant hard capsules
14 trdih gastrorezistentnih kapsul
Talk to your doctor before taking Nexium Control if:
Pred začetkom jemanja zdravila Nexium Control se posvetujte z zdravnikom, če:
Adverse reactions such as dizziness and visual disturbances are uncommon (see section 4.8).
Neželeni učinek omotica se pojavlja občasno, motnje vida pa se pojavljajo redko (glejte poglavje 4.8).
Nexium Control contains sucrose
Zdravilo Nexium Control vsebuje saharozo
The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired.
Presnova esomeprazola je lahko okvarjena pri bolnikih z blagimi do zmernimi motnjami delovanja jeter.
Sodium hydroxide Titanium dioxide (E171)
Tiskarsko črnilo povidon K-17 propilenglikol šelak natrijev hidroksid titanov dioksid (E171)
It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms.
Za izboljšanje simptomov je morda potrebno jemanje tablet 2 ali 3 dni zapored.
How to take Nexium Control
Kako jemati zdravilo Nexium Control
• Swallow your tablet whole with half a glass of water.
• Tableto zaužijte celo s pol kozarca vode.
What Nexium Control looks like and contents of the pack Nexium Control 20 mg gastro-resistant tablets are light pink, oblong, biconvex, 14 mm x 7 mm, filmcoated, engraved with ‘20 mG' on one side and A/EH on the other side.
Zdravilo Nexium Control 20 mg gastrorezistentne tablete so svetlorožnate, podolgovate, na obeh straneh izbočene (bikonveksne) 14 mm x 7 mm filmsko obložene tablete z vtisnjeno oznako "20 mG" na eni strani in A/EH na drugi strani.
Rare (may affect up to 1 in 1,000 people)
Redki (pojavijo se lahko pri največ 1 od 1.000 oseb)
If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor.
Bolniku je treba naročiti, da se mora posvetovati z zdravnikom, če po 2 tednih stalnega zdravljenja ni olajšanja simptomov.
Subacute cutaneous lupus erythematosu s (see section
subakutni kožni eritematozni lupus (glejte poglavje
Esomeprazole is a CYP2C19 inhibitor.
Esomeprazol zavira CYP2C19.
Esomeprazole is acid labile and is administered orally as enteric-coated granules.
Esomeprazol je v kislem okolju nestabilen, zato se peroralno uporablja v obliki gastrorezistentnih zrnc.
No gender difference is seen after repeated once-daily administration.
Po večkratnem odmerjanju enkrat na dan niso ugotovili razlik med spoloma.
• Swallow your capsule whole with half a glass of water.
• Kapsulo zaužijte celo s pol kozarca vode.
These gastric effects in the rat are the result of sustained, pronounced hypergastrinaemia secondary to reduced production of gastric acid and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion.
Ti učinki na želodec pri podganah so posledica stalne, izrazite hipergastrinemije zaradi manjšega nastajanja želodčne kisline.
For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended.
Ugotovljeno je, da se je koncentracija atazanavirja in nelfinavirja v serumu med sočasno uporabo z omeprazolom zmanjšala, zato takšna sočasna uporaba ni priporočljiva.
It might be necessary to take the capsules for 2-3 consecutive days to achieve improvement of symptoms.
Za izboljšanje simptomov je morda potrebno jemanje kapsul 2 ali 3 dni zapored.
EU/1/13/860/003 14 gastro-resistant hard capsules
EU/1/13/860/003 14 trdih gastrorezistentnih kapsul
An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in some patients during long-term treatment with esomeprazole.
Pri nekaterih bolnikih so med dolgotrajnim zdravljenjem z esomeprazolom opažali več enterokromafinim podobnih celic; to je morda posledica večje koncentracije gastrina v serumu.
• When your reflux symptoms have completely gone you should stop taking this medicine.
• Nehajte jemati to zdravilo, ko simptomi refluksa popolnoma izginejo.
Do not chew, crush or open the capsule.
Kapsule ne žvečite, drobite ali odpirajte.
Titanium dioxide (E171)
titanov dioksid (E171) rumeni železov oksid (E172)
• Phenytoin (used to treat epilepsy)
• fenitoin (uporablja se za zdravljenje epilepsije)
• You get stomach pain or signs of indigestion such as nausea, fullness, bloating especially after food intake.
občutek polnosti ali napenjanje, zlasti po zaužitju hrane,
Therapeutic monitoring of digoxin should then be reinforced.
V takšnih okoliščinah je potreben poostreni nadzor koncentracije digoksina v plazmi.
The use of esomeprazole with clopidogrel should be discouraged (see section 4.5).
Esomeprazola in klopidogrela naj ne bi uporabljali skupaj (glejte poglavje 4.5).
Monitoring is recommended when initiating and ending concomitant esomeprazole treatment during treatment with warfarin or other coumarine derivatives.
Zato so v primeru zdravljenja z varfarinom ali drugimi kumarinskimi preparati ob uvedbi ali prenehanju sočasne uporabe esomeprazola priporočljive kontrole.
The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the area under the plasma concentration-time curve of esomeprazole.
Površina pod krivuljo plazemske koncentracije esomeprazola po času se pri takšnih bolnikih podvoji.
Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.
Ledvice so odgovorne za izločanje presnovkov esomeprazola, ne pa za odstranjevanje matičnega zdravila.
• They have had previous gastric ulcer or gastrointestinal surgery.
• če so kdaj imeli ulkus na želodcu ali operacijo prebavil.
Talk to your doctor as soon as possible if you experience any of the following signs of infection: This medicine may in very rare cases affect the white blood cells leading to immune deficiency.
To zdravilo lahko v zelo redkih primerih neugodno vpliva na bele krvne celice in povzroči imunsko pomanjkljivost.
Dose adjustment is not required in patients with mild to moderate liver impairment.
Bolnikom z blago do zmerno okvaro jeter odmerka ni treba prilagoditi.
When given together with PPIs, methotrexate levels have been reported to increase in some patients.
Pri nekaterih bolnikih so med uporabo skupaj z zaviralci protonske črpalke opazili zvišanje koncentracije metotreksata.
The following adverse reactions have been identified or suspected in the clinical studies programme for esomeprazole and post-marketing.
V programu kliničnih študij esomeprazola in med uporabo zdravila po prihodu na trg so bili ugotovljeni ali domnevni naslednji neželeni učinki zdravila.
It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn.
Ob uvedbi ali prenehanju zdravljenja z esomeprazolom je priporočljivo spremljati koncentracijo fenitoina v plazmi.
Always take this medicine exactly as described in this leaflet or as your pharmacist has told you.
Pri jemanju tega zdravila natančno upoštevajte napotke v tem navodilu ali navodila farmacevta.
Each gastro-resistant hard capsule contains 20 mg esomeprazole (as magnesium trihydrate).
Ena trda gastrorezistentna kapsula vsebuje 20 mg esomeprazola (v obliki magnezijevega trihidrata).
Each gastro-resistant tablet contains 20 mg esomeprazole (as magnesium trihydrate).
Ena gastrorezistentna tableta vsebuje 20 mg esomeprazola (v obliki magnezijevega trihidrata).
The co-administration of omeprazole (20 mg once a day) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared with the exposure observed with atazanavir 300 mg/ritonavir 100 mg once a day without omeprazole 20 mg once a day.
Sočasna uporaba omeprazola (20 mg enkrat na dan) s 400 mg atazanavirja/100 mg ritonavirja je pri zdravih prostovoljcih zmanjšala izpostavljenost atazanavirju za približno 30 % v primerjavi z izpostavljenostjo ob uporabi 300 mg atazanavirja/100 mg ritonavirja enkrat na dan brez 20 mg omeprazola enkrat na dan. Sočasna uporaba z omeprazolom (40 mg enkrat na dan) je povprečno AUC, Cmax in Cmin nelfinavirja zmanjšala za 36-39 %, povprečno AUC, Cmax in Cmin farmakološko aktivnega presnovka M8 pa za 75-92 %.
Each gastro-resistant capsule contains 20 mg esomeprazole (as magnesium trihydrate).
Ena gastrorezistentna kapsula vsebuje 20 mg esomeprazola (v obliki magnezijevega trihidrata).
Nexium Control 20 mg gastro-resistant tablets
Nexium Control 20 mg gastrorezistentne tablete
How to store Nexium Control
Shranjevanje zdravila Nexium Control
Nexium Control 20 mg gastro-resistant tablets esomeprazole
Nexium Control 20 mg gastrorezistentne tablete esomeprazol
In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4.
Pri slabih metabolizatorjih presnovo esomeprazola verjetno v glavnem katalizira
Nexium Control 20 mg gastro-resistant capsules esomeprazole
Nexium Control 20 mg gastrorezistentne kapsule esomeprazol
Dose adjustment is not required in patients with impaired renal function.
Bolnikom z okvarjenim delovanjem ledvic odmerka ni treba prilagoditi.
Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction.
Zato največji odmerek, pri bolnikih s hudimi motnjami delovanja jeter, ne sme preseči 20 mg. Esomeprazol in njegovi glavni presnovki med uporabo enkrat na dan ne kažejo težnje h kopičenju.
(the acid pump) and inhibits both basal and stimulated acid secretion.
Zavre bazalno in stimulirano izločanje želodčne kisline.
• Feeling sick (nausea) or being sick (vomiting).
• siljenje na bruhanje (slabost v želodcu) ali bruhanje
Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical studies (and also from post-marketing use).
Med neželenimi učinki, ki so bili v kliničnih študijah (in tudi med uporabo zdravila po prihodu na trg) opisani najpogosteje, so glavobol, bolečine v trebuhu, driska in navzea.
• You should seek urgent medical advice if you experience chest pain with light-headedness, sweating, dizziness or shoulder pain with shortness of breath.
• če se pojavijo bolečine v prsnem košu z omotico, potenje, vrtoglavica ali bolečina v rami z zasoplostjo, morate takoj poiskati nujno zdravniško pomoč;
Seek urgent medical attention if you experience chest pain with light-headedness, sweating, dizziness or shoulder pain with shortness of breath.
Če se pojavijo bolečine v prsnem košu z omotico, potenje, vrtoglavica ali bolečina v rami z zasoplostjo, morate takoj poiskati nujno zdravniško pomoč.
• Cisapride (used for indigestion and heartburn)
• cisaprid (uporablja se za zdravljenje težav z želodcem in zgage)
Interstitial nephritis
Bolezni sečil intersticijski nefritis
Nexium Control 20 mg gastro-resistant hard capsules esomeprazole
Nexium Control 20 mg trde gastrorezistentne kapsule esomeprazol
Do not chew, crush or open capsule.
Kapsul ne smete žvečiti, zdrobiti ali odpreti.
Sugar spheres (sucrose and maize starch) Talc
natrijev stearilfumarat sladkorne kroglice (saharoza in koruzni škrob) smukec titanov dioksid (E171) trietilcitrat
Your doctor may adjust your dose of Nexium Control if you also have severe liver problems and are treated for a long period of time.
Vaš zdravnik vam bo morda prilagodil odmerek zdravila Nexium Control,
What you need to know before you take Nexium Control 3.
Kaj je zdravilo Nexium Control in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Nexium Control Kako jemati zdravilo Nexium Control Možni neželeni učinki
Nexium Control 20 mg gastro-resistant hard capsules
Nexium Control 20 mg trde gastrorezistentne kapsule
• Muscle weakness
• omotica, mravljinčenje
Hands should be washed after handling the medicine.
Po dajanju zdravila si je treba umiti roke.
The full EPAR for MiPet Easecto can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila MiPet Easecto je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
This medicine is the same as Simparica, which is already authorised in the EU.
To zdravilo je enako zdravilu Simparica, ki je že odobreno v Evropski uniji (EU).
Because fleas and ticks must start feeding on the dog in order to be killed by the medicine, the risk of transmission of diseases with which they may be infected cannot be excluded.
Ker se morajo bolhe in klopi začeti hraniti s krvjo psa, da bi jih zdravilo lahko uničilo, ni mogoče izključiti tveganja za prenos bolezni, s katerimi so ti zajedavci morda okuženi.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that MiPet Easecto's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila MiPet Easecto večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The European Commission granted a marketing authorisation valid throughout the EU for MiPet Easecto on 31 January 2018.
Evropska komisija je dovoljenje za promet z zdravilom MiPet Easecto, veljavno po vsej Evropski uniji, izdala 31/01/2018.
This is a summary of the European public assessment report (EPAR) for MiPet Easecto.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo MiPet Easecto.
Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart.
Zdravljenje je treba nadaljevati, dokler kožni ostružki niso negativni pri vsaj dveh zaporednih pregledih, med katerima mora biti enomesečni razmik.
MiPet Easecto is available as chewable tablets (5, 10, 20, 40, 80 and 120 mg) and can only be obtained with a prescription.
Zdravilo MiPet Easecto je na voljo v obliki žvečljivih tablet (5, 10, 20, 40, 80 in 120 mg), njegovo predpisovanje in izdaja pa je le na recept.
MiPet Easecto was as effective as moxidectin/imidacloprid and the percentage of MiPet Easecto-treated dogs with no live mites was 15%, 69%, 93%, 94%, 100% and 100% on days 30, 60, 90, 120, 150 and 180, respectively.
Zdravilo MiPet Easecto je bilo enako učinkovito kot moksidektin/imidakloprid, pri čemer je bil delež psov, ki so bili zdravljeni z zdravilom MiPet Easecto in niso kazali znakov prisotnosti živih garjavcev, 15 %, 69 %, 93 %, 94 %, 100 % in 100 % na 30., 60., 90., 120., 150. oziroma 180. dan po opravljenem zdravljenju.
However, the following side effects are seen in less than 1 dog in 10,000: mild and short-lived vomiting and diarrhoea as well as tremor (shaking), ataxia (inability to coordinate body movements) or convulsions.
Vendar pa so pri manj kot 1 psu od 10 000 opazili naslednje neželene učinke: blago in kratkotrajno bruhanje in drisko ter tremor (tresenje), ataksijo (nezmožnost usklajenega gibanja telesa) ali konvulzije.
This authorisation was based on the authorisation granted to Simparica in 2015 (‘informed consent').
Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom Simparica, ki je bilo izdano leta 2015 (uporaba dokumentacije s soglasjem).
It is not intended to provide practical advice on how to use MiPet Easecto.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Other information about MiPet Easecto
Druge informacije o zdravilu MiPet Easecto
The effectiveness of MiPet Easecto against fleas was investigated in a field study in dogs infested with at least five live fleas.
Učinkovitost zdravila MiPet Easecto proti bolham so raziskovali v terenski študiji, v katero so bili vključeni psi z vsaj petimi živimi bolhami.
The company that makes Simparica has agreed that its scientific data can be used for MiPet Easecto (‘informed consent').
Družba, ki proizvaja zdravilo Simparica, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo MiPet Easecto (uporaba dokumentacije s soglasjem).
What is MiPet Easecto and what is it used for?
Kaj je zdravilo MiPet Easecto in za kaj se uporablja?
What are the risks associated with MiPet Easecto?
Kakšna tveganja so povezana z zdravilom MiPet Easecto?
MiPet Easecto can be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites).
Zdravilo MiPet Easecto se lahko uporablja kot del zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh).
What benefits of MiPet Easecto have been shown in studies?
Kakšne koristi je zdravilo MiPet Easecto izkazalo v študijah?
Side effects with MiPet Easecto are not common.
Neželeni učinki zdravila MiPet Easecto niso pogosti.
MiPet Easecto is a veterinary medicine used to treat infestations with ticks and fleas, demodectic and sarcoptic mange (skin infestations caused by two different types of mites) and ear mite infestations in dogs.
Zdravilo MiPet Easecto je zdravilo za uporabo v veterinarski medicini, ki je namenjeno zdravljenju infestacij s klopi in bolhami, garjavci vrste Demodex canis in Sarcoptes scabiei (kožne garjavosti, ki jo povzročata dve vrsti garjavcev) ter infestacij z ušesnimi garjavci pri psih.
The active substance in MiPet Easecto, sarolaner acts as an ‘ectoparasiticide'.
Zdravilna učinkovina v zdravilu MiPet Easecto, sarolaner, deluje kot ektoparaziticid.
Why is MiPet Easecto approved?
Zakaj je bilo zdravilo MiPet Easecto odobreno?
For MiPet Easecto the percentage of dogs with no live ear mites present was 91% at day 30 increasing to 99% on day 60, following two treatments.
Pri zdravljenju z zdravilom MiPet Easecto je bil delež psov, pri katerih na 30. dan po zdravljenju ni bilo več prisotnih živih ušesnih garjavcev, 91 %, ta pa je na 60. dan, tj. po dveh zdravljenjih, narastel na 99 %.
Safety information has been included in the summary of product characteristics and the package leaflet for MiPet Easecto, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
V povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
For treatment of sarcoptic mange, MiPet Easecto is given monthly for two consecutive months.
Za zdravljenje infestacij z garjami vrste Sarcoptes scabiei se zdravilo MiPet Easecto daje mesečno dva meseca zapored.
MiPet Easecto was as effective as moxidectin/imidacloprid.
Zdravilo MiPet Easecto je bilo enako učinkovito kot moksidektin/imidakloprid.
For more information about treatment with MiPet Easecto, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za več informacij o zdravljenju z zdravilom MiPet Easecto naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.